Investigators evaluated ctDNA as a prognostic marker for patients with follicular lymphoma in the phase III GALLIUM trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results